| Irubis–OTHER: investment, 202210 seed financing round totalling €2.8m incl business angels as co-investors |
2022-10-06 |
| Irubis–SEVERAL: investment, 202210 seed financing round €2.8m led by HTGF + Verve Ventures + Ventura BioMed Investors |
2022-10-06 |
| Irubis–TU Munich: investment, 202210 seed financing round totalling €2.8m incl co-investor Initiative for Industrial Innovators |
2022-10-06 |
| Irubis–Ventura Biomed Investors: investment, 202210 seed financing round totalling €2.8m incl co-lead investor Ventura Biomed Investors |
2022-10-06 |
| Irubis–Verve Capital Partners: investment, 202210 seed financing round totalling €2.8m incl co-lead investor Verve Ventures |
2022-10-06 |
| Agilent–Scitara: lab informatics, 202209– collab product integration of OpenLab CDS + SLIMS with Scientific Integration Platform SIP + DLX |
2022-09-21 |
| ValitaCell–Danaher: investment, 202209 acquisition of ValitaCell by Beckman Coulter Life Sciences |
2022-09-13 |
| 2bind–Dynamic Biosensors: switchSENSE technology, 202209– collab technology-service with 2bind using HeliX biosensor system as certified beta customer |
2022-09-01 |
| Agilent–Bright Giant: mass spectrometry software, 202208– collab developm s/w for AI-based small-molecule identification in mass spec metabolomics |
2022-08-16 |
| Trace Analytics–908 Devices: investment, 202208 acquisition $15.3m upfront cash + $2m cash milestones |
2022-08-09 |
| Atlas Antibodies–Genovis: MS-based analysis of biopharmaceuticals, 202208– supply service LC-MS analytics of recombinant CHO-antibodies to Evitria |
2022-08-08 |
| Polymer Standards Service–Agilent: investment, 202208 acquisition €na of PSS by Agilent |
2022-08-02 |
| NeoSphere Biotechnologies–SEVERAL: investment, 202207 financing round Series A €6m |
2022-07-25 |
| Namocell–Bio-Techne: investment, 202206–202207 acquisition $101.2m of Namocell by Bio-Techne |
2022-06-22 |
| SPT Labtech–EQT: investment, 202206– acquisition £650m of SPT Labtech by EQT IX Fund from Battery Ventures |
2022-06-22 |
| ModuVision–Knauer: investment, 202206 acquisition of ModuVision by Knauer |
2022-06-13 |
| Peptone–Bessemer Venture: investment, 202206 financing round Series A totalling $40m incl co-lead investor Bessemer Venture Partners |
2022-06-09 |
| Peptone–F-Prime: investment, 202206 financing round Series A totalling $40m incl co-lead investor F-Prime Capital |
2022-06-09 |
| Peptone–Hoxton Ventures: investment, 202206 financing round Series A totalling $40m incl existing + co-investor Hoxton Ventures |
2022-06-09 |
| Peptone–Novartis: investment, 202206 financing round Series A totalling $40m incl existing + co-investor dRX Capital |
2022-06-09 |
| Peptone–Nvidia: AI-based drug discovery, 202206 collab incl use of Nvidia DGX A100 supercomputer to run Peptone’s algorithmic engine |
2022-06-09 |
| Peptone–SEVERAL: investment, 202206 financing round Series A $40m led by F-Prime + Bessemer Venture Partners |
2022-06-09 |
| Peptone–Walden Catalyst: investment, 202206 financing round Series A totalling $40m incl co-investor Walden Catalyst Vemtures |
2022-06-09 |
| Agilent–Mettler-Toledo: lab automation, –202206 collab developm + product integration automated + digitalised sample prep for LC/GC workflow |
2022-06-01 |
| CatSci–Keensight Capital: investment, 202206 investment by Keensight Capital to support expansion |
2022-06-01 |
| Weezion–Mérieux: in-vitro diagnostics, 202206– collab technical assistance from bioMérieux to develop MS-based sepsis IVD |
2022-06-01 |
| Weezion–Mérieux: investment, 202206 investment €2m from bioMérieux for a 4.26% share accompanied by technical assistance |
2022-06-01 |
| Irubis–EU (govt): grant, 202005– grant €1.3m from EIC Accelerator Pilot Programme |
2022-05-26 |
| OMass–Consilium: public relations, 202204 service existent by Consilium Strategic Communications |
2022-04-28 |
| OMass–SEVERAL: investment, 202204 financing round Series B £75.5m led by new investors GV + Northpond Ventures + Sanofi Ventures |
2022-04-28 |
| Debiopharm–Dotmatics: data integration + analysis s/w, 202204 supply existent Debiopharm is customer of Dotmatics |
2022-04-26 |
| Peak Proteins–Sygnature Discovery: investment, 202204 acquisition €na of Peak Proteins by Sygnature Discovery |
2022-04-26 |
| PerkinElmer–Scitara: lab informatics, 202204– collab product integration of Signals informatics platform with Scientific Integration Platform SIP |
2022-04-14 |
| Refeyn–Foresight Group: investment, 202204 financing round Series B incl existing + co-investor Foresight Group |
2022-04-11 |
| Refeyn–Horizons Ventures: investment, 202204 financing round Series B incl existing + co-investor Horizons Ventures |
2022-04-11 |
| Refeyn–Northpond Ventures: investment, 202204 financing round Series B incl lead investor Northpond Ventures |
2022-04-11 |
| Refeyn–Oxford Science Enterprises: investment, 202204 financing round Series B incl existing + co-investor OSE |
2022-04-11 |
| Refeyn–SEVERAL: investment, 202204 financing round Series B led by Northpond Ventures |
2022-04-11 |
| Refeyn–Univ Oxford: investment, 202204 financing round Series B incl existing + co-investor Univ Oxford |
2022-04-11 |
| Enable Medicine–SEVERAL: investment, 202204 financing round Series A $60m led by Anthos Capital + General Catalyst |
2022-04-07 |
| IonSense–Bruker: investment, 202204 acquisition of IonSense by Bruker |
2022-04-06 |
| Optimal Industrial–Bruker: investment, 202204 acquisition $40.3m of Optimal Industrial Automation + Technologies by Bruker |
2022-04-05 |
| Irubis–EU (govt): credit, 202203– convertible loan €500k from EIC Fund as part of EIC Accelerator Pilot programme |
2022-03-24 |
| Biogenity–Denmark (govt): investment, 202203 Innovation Fund Denmark invests in Innobooster project BioSWITCH |
2022-03-23 |
| PrognomiQ–Bruker: investment, 202203 financing round totalling $46m incl lead investor Bruker Corp |
2022-03-15 |
| PrognomiQ–SEVERAL: investment, 202203 financing round $46m led by Bruker Corp |
2022-03-15 |
| Fluidigm–Casdin Capital: investment, 202201–202204 acquisition totalling $250m zero-coupon convertible preferred shares incl Casdin Capital |
2022-01-24 |
| Fluidigm–SEVERAL: investment, 202201–202204 acquisition $250m zero-coupon convertible preferred shares by Casdin Capital + Viking Global Investors |
2022-01-24 |
| Fluidigm–Viking Global Investors: investment, 202201–202204 acquisition totalling $250m zero-coupon convertible preferred shares incl Viking |
2022-01-24 |
| Prolab Instruments–Bruker: investment, 202201 acquisition €na of Prolab Instruments Gmbh by Bruker |
2022-01-19 |
| PreOmics–Bruker: investment, 202201 acquisition €na of shares of HTGF + Think.Health Ventures + certain business angels by Bruker |
2022-01-18 |
| PreOmics–Bruker: investment, 202201 Series B investment €13.5m from Bruker tog w secondary transaction making Bruker majority shareholder |
2022-01-18 |
| Omiq–Insightful Science: investment, 202201 acquisition of Omiq Inc by Insightful Science |
2022-01-13 |
| ProtaGene–Ampersand: investment, 202201 existent portfolio company after merger/acquisition of PPS GmbH + BioAnalytix + GeneWerk GmbH in 7/21 |
2022-01-12 |
| Rockefeller Univ–Lumicks: microscope, 202201 supply of Quadrupole C-Trap system to lab of Prof Michael O’Donnell |
2022-01-12 |
| Creoptix–Spectris: investment, 202201 acquisition of Creoptix AG by Malvern Panalytical |
2022-01-11 |
| Scitara–Flybridge Capital: investment, 202201 financing round Series B totalling $15m incl existing + co-investor Flybridge Capital |
2022-01-11 |
| Scitara–Northpond Ventures: investment, 202201 financing round Series B totalling $15m incl existing + lead investor Northpond Ventures |
2022-01-11 |
| Scitara–Scott Partnership: public relations, 202201 service existent by Scott PR |
2022-01-11 |
| Scitara–SEVERAL: investment, 202201 financing round Series B $15m led by Northpond Ventures |
2022-01-11 |
| GSK–908 Devices: mass spectrometer, 202201 supply GSK purchases 5th Rebel CE-MS-based cell culture media analyser from 908 Devices |
2022-01-07 |
| Exelead–Merck (DE): investment, 202201 acquisition $760m in cash by Merck |
2022-01-06 |
| Protai Bio–Grove Ventures: investment, 202201 seed financing round totalling $8m incl co-lead investor Grove Ventures |
2022-01-05 |
| Protai Bio–Pitango: investment, 202201 seed financing round totalling $8m incl co-lead investor Pitango HealthTech |
2022-01-05 |
| Protai Bio–SEVERAL: investment, 202201 seed financing round $8m co-led by Grove Ventures + Pitango HealthTech |
2022-01-05 |
| Bioclinica–ERT: investment, 2021–2022 merger to become Clario |
2022-01-01 |
| Protein Metrics–Insightful Science: investment, 202112 acquisition of Protein Metrics by Insightful Science |
2021-12-21 |
| Lonza–Agilent: analytical instruments, 202112– strategic alliance to integrate analytical technologies in Cocoon cell therapy production platform |
2021-12-15 |
| Merck (DE)–Merck (DE): investment, 202112 third increase of financial commitment by €600m in evergreen corporate venture fund M Ventures |
2021-12-08 |
| Molecubes–Bruker: investment, 202111 acquisition $21m by Bruker |
2021-11-19 |
| Axel Semrau–Trajan: investment, 202111 acquisition €19.85m by Trajan Group |
2021-11-18 |
| 908 Devices–SEVERAL: investment, 202111 public offering $100.8m net $94.4m with 3.15m shares common stock at $32/share |
2021-11-15 |
| Bruker–Bico: MS-based single cell proteomics, 202111– co-marketing of Cellenion’s cellenONE with timsTOF SCP mass spectrometers |
2021-11-15 |
| Thermo Fisher–Bico: MS-based single cell proteomics, 202111– co-marketing Cellenion’s cellenONE + proteoCHIP with Orbitrap MS systems + TMT technology |
2021-11-15 |
| LabArchives–Insightful Science: investment, 202111 acquisition of LabArchies by Insightful Science |
2021-11-10 |
| Danaher–Evosep: MS-based proteomics, 202111– collab developm proteomics workflows w joint customers using Evosep One + Sciex ZenoTOF 7600 system |
2021-11-01 |
| Sartorius–Waters: biopharma production technology, 202110– collab product integration BioAccord LC-MS as bioprocess analyzer with Ambr bioreactor |
2021-10-27 |
| DNA Script–Agilent: investment, 202110 financing round Series C totalling $165m incl existing + co-investor Agilent Technologies |
2021-10-26 |
| DNA Script–Danaher: investment, 202110 financing round Series C totalling $165m incl existing + co-investor Danaher Life Sciences |
2021-10-26 |
| DNA Script–SEVERAL: investment, 202110 financing round Series C $165m co-led by Coatue Management + Catalio Capital Management |
2021-10-26 |
| TrueMass–Scott Partnership: public relations, 202110 service existent by Scott PR |
2021-10-26 |
| QInstruments–Bico: investment, 202110 acquisition 100% cash/debt free for €58.25m upfront + €3m milestones thereof 13% paid in new Bico shares |
2021-10-01 |
| Thermo Fisher–Carbon Engineering: analytical technology, 202109 collab existent direct air capture technology to reduce CO2 emissions |
2021-09-23 |
| Hurel–Bico: investment, 202109 acquisition $2.5m of assets + operations of Hurel Corp + integration in Visikol |
2021-09-15 |
| Agena Bioscience–Mesa Labs: investment, 202109– acquisition $300m in cash of Agena by Mesa Laboratories ANNOUNCED |
2021-09-14 |
| De Novo Software–Insightful Science: investment, 202109 acquisition of De Novo Software by Insightful Science |
2021-09-14 |
| Evotec–Biognosys: MS-based proteomics, 202109– collab integration of Spectronaut proteomics data analys into drug discovery + clinical proteomics |
2021-09-14 |
| Owlstone–Horizons Ventures: investment, 202109 financing round Series D totalling $58m incl existing + lead investor Horizons Ventures |
2021-09-07 |
| Owlstone–SEVERAL: investment, 202109 financing round Series D $58m of Owlstone Medical led by existing investor Horizons Ventures |
2021-09-07 |
| Biognosys–ETH Zürich: LiP technology, 202108 collab developm + excl license from Institute of Systems Biology |
2021-08-27 |
| Atavistik Bio–Column Group: investment, 202108 financing round Series A totalling $60m incl lead investor The Columm Group |
2021-08-24 |
| Atavistik Bio–Lux Capital: investment, 202108 financing round Series A totalling $60m incl co-investor Lux Capital |
2021-08-24 |
| Atavistik Bio–Nextech: investment, 202108 financing round Series A totalling $60m incl co-investor Nextech Invest Ltd |
2021-08-24 |
| Atavistik Bio–SEVERAL: investment, 202108 financing round Series A $60m led by The Columm Group with Lux Capital + Nextech Invest |
2021-08-24 |
| Thermo Fisher–ChromSword: HPLC software, –202108 collab developm + launch of Vanquish Method Development HPLC + UHPLC system using ChromSword s/w |
2021-08-16 |
| Spectricity–SEVERAL: investment, 202108 financing round Series B €14m |
2021-08-03 |
| Nuvisan–ALS Ltd: investment, 202207 strategic investment acquiring 49% stake in Nuvisan to expand ALS Life Sciences network |
2021-07-28 |
| BioLegend–PerkinElmer: investment, 202107– acquisition $5.25b in cash + shares subject to certain adjustments ANNOUNCED |
2021-07-26 |
| Excellims–Covalent Bonds: public relations, 202107 service existent by Covalent Bonds |
2021-07-21 |
| Mobilion–Agilent: investment, 202107 financing round Series C totalling $60m incl existing + co-investor Agilent Technologies |
2021-07-13 |
![[MSC] Mass-Spec-Capital.com The Mass Spectrometry Web Portal](/images/basics/msc-mass-spec-capital-portal-logo.svg){kind=logo}
1 2 3 4 5 6 7 
Date
![Picture [iito] LSE iitoLifeScience Life Sciences Mass Spec 120x120px](/banner/iito-business-intelligence-20230710-120-120-twitter-iitolifescience-germany-europe-mass-spec.jpg)
![Picture [LSUS] Life-Sciences-USA.com – The Business Web Portal 120x600px](/banner/iito-20181119-120-600-lsus-life-sciences-usa-com.jpg)
